Sansure Biotech (SHA:688289) obtained certification from the European Union's regulator for in vitro diagnostic medical devices for five nucleic acid testing products, according to a Tuesday filing with the Shanghai bourse.
These include kits for human papillomavirus genotyping, respiratory virus multiplex detection, and quantification of human immunodeficiency, Hepatitis B and Hepatitis C viruses.
Shares of the biotechnology company closed 1% lower Tuesday.